Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

Nobels, Frank; d'Hooge, D; Crenier, Laurent

doi:10.1185/03007995.2012.695730

Cited by 6 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies published since the prior review have confirmed using continuous glucose monitoring that BIAsp 30 has a more favorable PD effect than BHI 30 [ 2 ] and fewer glucose fluctuations than a basal–bolus regimen [ 3 ]. Results from the large, prospective, multinational A 1 chieve study have expanded on results from previously reported RCTs and have shown that patients in real-life clinical practice using BHI 30 can realize clinical benefit from switching to BIAsp 30 [ 15 , 17 ] as well as improvements in quality of life [ 15 , 16 ]. Also consistent with previous work are several studies demonstrating that BIAsp 30 is safe and effective when used in insulin-naïve patients in primary care practice [ 7 – 9 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

et al. 2018

View full text Add to dashboard Cite

Since clinical experience with biphasic insulin aspart 30 (BIAsp 30) in type 2 diabetes mellitus (T2DM) was reviewed in 2012 after 10 years of use worldwide, additional studies have been published that highlight new aspects, including use in real-world populations. Evidence from 35 new studies confirms and builds upon previous work indicating that BIAsp 30 continues to have pharmacodynamic and clinical advantages over biphasic human insulin (BHI 30), including in real-world practice with unselected populations of patients. BIAsp 30 has also been shown to be safe and efficacious as an add-on to dipeptidyl peptidase-4 (DPP-4) inhibitors. Intensification with BIAsp 30 is a safe and effective way to improve glycemic control, and titration performed by patients can achieve results that are at least comparable to those when being guided by healthcare providers. Stepwise intensification using BIAsp 30 is comparable to intensification using a basal–bolus regimen, and twice-daily BIAsp 30 provides similar glycemic control to a basal-plus regimen. Data from large observational studies, in particular, have identified patient-related characteristics that are associated with improved clinical responses, suggesting that earlier initiation and intensification of therapy is warranted. Finally, new health-economic analyses continue to confirm that BIAsp 30 is cost effective versus other therapies such as BHI 30, neutral protamine Hagedorn (NPH), or insulin glargine in both insulin-naïve and insulin-experienced patients. After 15 years of clinical use worldwide, analysis of more recent 5-year data indicates that BIAsp 30 remains a safe, effective, and simple-to-use insulin for initiation and intensification by diabetes specialists and primary care physicians in a variety of patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Another observational study in Belgium and Luxembourg followed 592 patients at 12 and 26 weeks after switching from BHI 30 to BIAsp 30, BIAsp 50, or BIAsp 70 [ 17 ]. About two-thirds of patients took BIAsp 30 and one-third BIAsp 50, with few patients using BIAsp 70.…”

Section: Initiating Insulin Therapy With Biasp 30mentioning

confidence: 99%

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[ 14 15 ] Significant improvements in mean HbA 1c were also noted in patients who switched from BHI 30 or 50 to BIAsp 30, 50 or 70 in routine clinical practice in another 26 weeks observational study. [ 16 ]…”

Section: Discussionmentioning

confidence: 99%

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A ₁ chieve study

Kalra

Akhtar

et al. 2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Aim:The aim of the following study is to evaluate the safety and effectiveness of switching from biphasic human insulin (BHI) to biphasic insulin aspart 30 (BIAsp 30) in Indian patients with type 2 diabetes as a sub-analysis of the 24-week, non-interventional A1chieve study.Materials and Methods:Indian patients switching from BHI to BIAsp 30 based on the physicians’ decisions were included. The primary outcome was the incidence of serious adverse drug reactions (SADRs), including major hypoglycemic events; secondary outcomes included changes in hypoglycemia in the 4 weeks preceding baseline and week 24 and changes from baseline to week 24 in glycated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), body weight and quality of life (QoL).Results:Overall, 1976 patients (mean ± standard deviation age, 55.1 ± 10.6 years and diabetes duration, 10.1 ± 5.3 years) on a mean pre-study BHI dose of 0.44 ± 0.18 U/kg were included. The mean BIAsp 30 dose was 0.43 ± 0.17 U/kg at baseline and 0.44 ± 0.17 U/kg at week 24. No SADRs were reported. The proportion of patients reporting overall hypoglycemic events reduced significantly from baseline to week 24 (15.0% vs. 2.9%, P < 0.0001). The mean HbA1c level improved significantly from 9.1 ± 1.4% at baseline to 7.5 ± 1.0% at week 24, along with improvements in FPG, post-breakfast PPPG and QoL (P < 0.001). The mean body weight decreased from 69.3 ± 10.8 kg at baseline to 69.1 ± 10.4 kg at week 24 (P = 0.003).Conclusion:Switching from BHI to BIAsp 30 therapy was well-tolerated and was associated with improved glycemic control.

show abstract

“…This observational trial suggests patterns of prescription premixed insulin that would be appropriate for an average practice. [ 11 ]…”

Section: Linical D Atamentioning

confidence: 99%

High-mix insulins

Kalra

Farooqi

Elhouni³

2015

Indian J Endocr Metab

View full text Add to dashboard Cite

Premix insulins are commonly used insulin preparations, which are available in varying ratios of different molecules. These drugs contain one short- or rapid-acting, and one intermediate- or long-acting insulin. High-mix insulins are mixtures of insulins that contain 50% or more than 50% of short-acting insulin. This review describes the clinical pharmacology of high-mix insulins, including data from randomized controlled trials. It suggests various ways, in which high-mix insulin can be used, including once daily, twice daily, thrice daily, hetero-mix, and reverse regimes. The authors provide a rational framework to help diabetes care professionals, identify indications for pragmatic high-mix use.

show abstract

Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

Abstract: Patients with long-standing type 2 diabetes can switch safely from BHI to BIAsp therapy, even if they receive intensified treatment, and they have no problems changing the timing of their insulin injections.

Cited by 6 publications

References 33 publications

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A ₁ chieve study

High-mix insulins

Contact Info

Product

Resources

About

Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results

Abstract: Patients with long-standing type 2 diabetes can switch safely from BHI to BIAsp therapy, even if they receive intensified treatment, and they have no problems changing the timing of their insulin injections.

Cited by 6 publications

References 33 publications

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

15 Years of Experience with Biphasic Insulin Aspart 30 in Type 2 Diabetes

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A 1 chieve study

High-mix insulins

Contact Info

Product

Resources

About

Clinical experience of switching from biphasic human insulin to biphasic insulin aspart 30 in Indian patients with type 2 diabetes in the A ₁ chieve study